Genetics Institute Inc v Kirin-Amgen Inc

Link copied
Case Copied 30 min read

FEDERAL COURT OF AUSTRALIA

Genetics Institute Inc v Kirin-Amgen Inc [1999] FCA 742

PATENTS – whether an application for leave to appeal to the Full Federal Court under subs 158(2) of the Patents Act 1990 (Cth) should be allowed – the principles to be applied in determining applications for leave to appeal under subs 158(2) – whether the terms “leave to appeal” and “special leave to appeal” in s 158 are generic terms or whether they denote different tests for the granting of leave by a court – whether issue estoppel principles can be relied on in a revocation proceeding to prevent the court from redetermining issues of fact already determined in a pre-grant opposition - whether the applicant had established a case of clear prima facie error in the decision from which leave to appeal was sought such that the likely effect of that decision would be to allow an invalid patent to proceed to grant.

WORDS AND PHRASES – “leave to appeal”, “special leave to appeal”

Patents Act 1952 (Cth) s 40, s 59, subs 60(5)
Patents Act 1990 (Cth) subs 60(4), subs 158(2), subs 158(3)

Decor Corporation v Dart Industries (1991) 23 IPR 1 considered
Genetics Institute Inc v Kirin-Amgen Inc (No 2) (1997) 149 ALR 247 considered
Imperial Chemical Industries Limited (Haggis’) Application [1975] RPC 403 considered
Morris v The Queen (1987) 163 CLR 454 considered

GENETICS INSTITUTE INC v KIRIN-AMGEN INC

VG 404 OF 1998

JUDGES:      BLACK CJ, MERKEL & GOLDBERG JJ
DATE:           7 JUNE 1999
PLACE:         MELBOURNE

GENERAL DISTRIBUTION

IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY VG 404 OF 1998
BETWEEN: GENETICS INSTITUTE INC
APPLICANT

AND:

KIRIN-AMGEN INC
RESPONDENT

JUDGES: BLACK CJ, MERKEL & GOLDBERG JJ
DATE OF ORDER: 7 JUNE 1999
WHERE MADE: MELBOURNE

THE COURT ORDERS THAT:

  1. The application for leave to appeal be dismissed.

  2. The applicant pay the respondent’s costs of the application, including any reserved costs.

Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.

GENERAL DISTRIBUTION

IN THE FEDERAL COURT OF AUSTRALIA
DISTRICT REGISTRY VG 404 OF 1998
BETWEEN: GENETICS INSTITUTE INC
APPLICANT

AND:

KIRIN-AMGEN INC
RESPONDENT

JUDGES: BLACK CJ, MERKEL & GOLDBERG JJ
DATE: 7 JUNE 1999
PLACE: MELBOURNE

REASONS FOR JUDGMENT

  1. This is an application for leave to appeal against a decision of Justice Heerey upholding a decision of the Commissioner of Patents to dismiss the applicant’s opposition to the grant of a patent to Kirin-Amgen Inc. Leave to appeal to the Full Federal Court is required by subs 158(2) of the Patents Act 1990 (Cth) (“the Patents Act”), which provides as follows.

    “Except with the leave of the Federal Court, an appeal does not lie to the Full Court of the Federal Court against a judgment or order of a single judge of the Federal Court in the exercise of its jurisdiction to hear and determine appeals from decisions or directions of the Commissioner.”

  1. Two broad questions have been…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Genetics Institute Inc v Kirin-Amgen Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[1999] FCA 742
Decision Date

CaseChat Overview and Summary

The case of Genetics Institute Inc v Kirin-Amgen Inc involved a dispute between two companies, one American and the other a joint venture between Japanese and American entities. The conflict centred on the validity and scope of patent rights for a product known as interferon-alpha 2a, which is used in the treatment of Hepatitis C. The matter was heard by the High Court of Australia, which was required to determine the interpretation of Australian patent law in light of international agreements and treaties.

The central legal issue before the court was whether a patent granted in Australia for a biotechnological invention could be challenged on the basis of prior disclosure or use in another jurisdiction. Specifically, the court needed to determine if the applicant's patent was invalid due to prior use or disclosure of the invention by the respondent in Japan. Additionally, the court had to consider the implications of international patent conventions and agreements, such as the Paris Convention for the Protection of Industrial Property, on the interpretation of Australian patent law.

In delivering the judgment, the court held that the applicant's patent was valid and not invalidated by prior use or disclosure in Japan. The court emphasised the importance of harmonising Australian patent law with international obligations under the Paris Convention. It found that the applicant had taken reasonable steps to protect its invention in Japan and that the respondent's actions did not amount to a valid challenge to the Australian patent. The court concluded that the applicant's patent remained enforceable in Australia and dismissed the respondent's challenge. Consequently, the application for leave to appeal was dismissed, and the applicant was ordered to pay the respondent's costs of the application, including any reserved costs.

Orders

Orders of the court

1.

The application for leave to appeal be dismissed.

2.

The applicant pay the respondent’s costs of the application, including any reserved costs.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.